BOSTON, MA
Humedica, a next-generation health care informatics company, announced the company’s official launch, along with the previous completion of its $30 million round of venture capital and its clinical analytics platform.
In response to a growing demand for essential clinical information, Humedica has developed a clinical informatics solution that addresses the specific needs of inpatient and outpatient health care providers, pharmaceutical and biotechnology firms, medical device manufacturers, government agencies and financial services firms. Currently being implemented in select hospitals and medical groups throughout the country, Humedica’s software-as-a-service (SaaS) solution connects patient information across varied medical settings and time periods to generate a comprehensive view of patient care.
“...Humedica offers a complete picture of health care delivery, bringing together clinical, operational, and financial data to help answer both pressing real-time questions and to address topics at the center of health care reform that require comparative analyses and benchmarking information,” said Michael Weintraub, President and CEO of Humedica.
Humedica has developed an analytics platform that effectively overcomes barriers of accessing relevant clinical information, transforming real-time and retrospective data into actionable knowledge. Humedica applies sophisticated techniques to mine, standardize, and aggregate health care data from disparate IT systems, all within a HIPAA-compliant, and highly secure environment.
Humedica’s SaaS-based clinical informatics portfolio offers analytics, reporting, and benchmarking.
The company also disclosed it received $30 million in capital from Bain Capital Ventures, General Catalyst Partners, North Bridge Venture Partners, and Leerink Swann.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.